{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:47:05Z","timestamp":1743450425861,"version":"3.37.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/olq.0b013e3181aad9df","type":"journal-article","created":{"date-parts":[[2009,9,23]],"date-time":"2009-09-23T13:25:20Z","timestamp":1253712320000},"page":"665-669","source":"Crossref","is-referenced-by-count":9,"title":["Antimicrobial Resistance in Gonorrhea: The Influence of Epidemiologic and Laboratory Surveillance Data on Treatment Guidelines: Alberta, Canada 2001\u20132007"],"prefix":"10.1097","volume":"36","author":[{"given":"Sabrina","family":"Plitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtiss","family":"Boyington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marguerite","family":"Lovgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Read","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameeta E.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 3","key":"R3-12-20210213","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1086\/511422","article-title":"Update on the management of gonorrhea in adults in the United States.","volume":"44","author":"Newman","year":"2007","journal-title":"Clin Infect Dis"},{"article-title":"Antimicrobial Resistance in Neisseria gonorrhoeae.","year":"2001","author":"Tapsall","key":"R4-12-20210213"},{"issue":"suppl 4","key":"R5-12-20210213","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1086\/430787","article-title":"Antibiotic resistance in Neisseria gonorrhoeae.","volume":"41","author":"Tapsall","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R6-12-20210213","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-147-2-200707170-00006","article-title":"Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance.","volume":"147","author":"Wang","year":"2007","journal-title":"Ann Intern Med"},{"key":"R7-12-20210213","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1503\/cmaj.080222","article-title":"Prevalence of and risk factors for quinolone resistant Neisseria gonorrhea infection in Ontario.","author":"Ota","year":"2009","journal-title":"CMAJ"},{"key":"R8-12-20210213","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1503\/cmaj.045088","article-title":"Gonorrhea treatment guidelines in Canada: 2004 update.","volume":"171","author":"Mann","year":"2004","journal-title":"CMAJ"},{"year":"2007","key":"R9-12-20210213","article-title":"Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement."},{"key":"R12-12-20210213","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections.","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R13-12-20210213","first-page":"27","article-title":"Comparison of the Cobas Amplicor (Roche) PCR Assay With Culture for N. gonorrhoeae Under Unique Clinical Conditions.","author":"Singh","year":"2003"},{"key":"R15-12-20210213","first-page":"48","article-title":"Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific region, 2006.","volume":"32","year":"2008","journal-title":"Commun Dis Intell"},{"key":"R16-12-20210213","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jac\/dkm434","article-title":"Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997\u20132006.","volume":"61","author":"Tapsall","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R17-12-20210213","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1086\/386312","article-title":"Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: Resistance surveillance and typing by molecular methodologies.","volume":"189","author":"Giles","year":"2004","journal-title":"J Infect Dis"},{"key":"R18-12-20210213","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-0463.2006.apm_332.x","article-title":"Molecular epidemiology of Neisseria gonorrhoeae: identification of the first presumed Swedish transmission chain of an azithromycin-resistant strain.","volume":"114","author":"Lundback","year":"2006","journal-title":"APMIS"},{"key":"R19-12-20210213","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/00007435-200212000-00008","article-title":"Characterization of ciprofloxacin resistance in Neisseria gonorrhoeae isolates in Canada.","volume":"29","author":"Ng","year":"2002","journal-title":"Sex Transm Dis"},{"key":"R20-12-20210213","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dkh345","article-title":"Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries.","volume":"54","author":"Yong","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R21-12-20210213","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3201\/eid1308.060948","article-title":"Threat to cefixime treatment for gonorrhea.","volume":"13","author":"Yokoi","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"R22-12-20210213","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1086\/377500","article-title":"Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001.","volume":"37","author":"Wang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R23-12-20210213","first-page":"435","article-title":"Availability of cefixime 400 mg tablets\u2013United States, April 2008.","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R24-12-20210213","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14787210.4.4.619","article-title":"Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: Some possible remedies.","volume":"4","author":"Tapsall","year":"2006","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Sexually Transmitted Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007435-200910000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T09:13:21Z","timestamp":1739351601000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007435-200910000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/olq.0b013e3181aad9df","relation":{},"ISSN":["0148-5717"],"issn-type":[{"type":"print","value":"0148-5717"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}